Drugs / Bonjesta
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | BONJESTA | — | 2016-11-07 | fda.gov ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05289557 Comparator | May 2022 → Dec 2027 | — | Duchesnay Inc. | Suspended | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bonjesta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05289557 ↗ |
| Route | Oral | “one tablet will be taken orally at bedtime” NCT05289557 ↗ |